HCP Consensus Statements from CJON
Published in August 2017, this supplement to Clinical Journal of Oncology Nursing provides consensus statements from the Melanoma Nursing Initiative (MNI) faculty on adverse event management and adherence promotion strategies for immunotherapies, targeted therapies, and intralesional therapies. Below is a brief description of each article, with a link to a downloadable PDF.
Editorial: Collaborative Care in Melanoma: The essential role of the nurse
This editorial by John Kirkwood, MD, and Antoni Ribas, MD, PhD, defines the clinical context for the MNI and the central role of the nurse in adverse event identification and management in melanoma.
Introduction: Advances in Melanoma: The rationale for the Melanoma Nursing Initiative
This introduction by chairperson Krista M. Rubin, RN, MS, FNP-BC, provides an overview of the supplement, with a specific focus on the rationale for the initiative and a discussion of the unique feature of the supplement—the care step pathways (CSPs).
BRAF/MEK Inhibitor Therapy: Consensus statement from the faculty of the Melanoma Nursing Initiative on managing adverse events and potential drug interactions
This article by Maria P. Czupryn, ARNP, AOCNP®, and Jennifer Cisneros, PharmD, illustrates how to recognize and manage adverse events associated with molecularly targeted oral therapies (i.e., cobimetinib, dabrafenib, trametinib, and vemurafenib). In addition, the article addresses strategies to recognize and manage potential drug–drug interactions with BRAF/MEK regimens.
Ipilimumab-Based Therapy: Consensus statement from the faculty of the Melanoma Nursing Initiative on managing adverse events with ipilimumab monotherapy and combination therapy with nivolumab
This article by Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP®, APHN, and Brianna Hoffner, RN, MSN, APN-BC, AOCNP®, reviews the often challenging tasks of recognizing and managing immune-related adverse events associated with ipilimumab-based therapy in the adjuvant and metastatic settings. The article addresses both ipilimumab monotherapy and combination therapy with nivolumab.
PD-1 Inhibitor Therapy: Consensus statement from the faculty of the Melanoma Nursing Initiative on managing adverse events
In this article, Suzanne McGettigan, MSN, CRNP, ANP-BC, AOCN®, and Krista M. Rubin, RN, MS, FNP-BC, review the appropriate use and immune-related adverse event management of therapy with PD-1 inhibitors pembrolizumab and nivolumab.
Intralesional Therapy: Consensus statements for best practices in administration from the Melanoma Nursing Initiative
In this article, Virginia Seery, MSN, RN, ANP-BC, discusses the infectious precautions, logistics requirements, administrative techniques, and adverse event management needed to provide optimal care to patients receiving intratumoral therapy with talimogene laherparepvec (T-VEC), a first-in-class oncolytic virus approved for use in melanoma.
Promoting Oral Therapy Adherence: Consensus statements from the faculty of the Melanoma Nursing Initiative on oral melanoma therapies
In this article, Lisa A. Kottschade, APRN, MSN, CNP, and Mollie Lehner Reed, MSN, RN, ACNP, describe ways to increase adherence to and promote patient engagement in oral melanoma therapies.